Wanbury Gets EDQM Approval For Rivaroxaban API and USFDA DMF Clearances

Market snapshot: Wanbury Limited has achieved significant global regulatory milestones by securing EDQM approval for its Rivaroxaban API alongside USFDA Drug Master File (DMF) clearances for Paroxetine HCl and Metformin HCl. These regulatory expansions broaden the company's export opportunities in European and US markets, providing long-term structural tailwinds despite recent operational profit headwinds.

Data Snapshot

• Net profit after tax for the quarter ended June 30, 2026, declined ≈75.98% YoY to ₹3.24 crore (derived: ₹3.24 crore vs ₹13.49 crore).
• Revenue from operations grew ≈1.47% YoY to ₹165.58 crore for the quarter ended June 30, 2026 (derived: ₹165.58 crore vs ₹163.18 crore).
• Wanbury refinanced high-cost debt of ₹205 crore, successfully bringing borrowing interest rates down to sub-10% per annum.

What's Changed

• Revenue from operations grew marginally to ₹165.58 crore for the quarter ended June 30, 2026, compared to ₹163.18 crore in the corresponding quarter last year.
• Net profit fell sharply to ₹3.24 crore from ₹13.49 crore YoY due to raw material cost surges and logistics disruptions in West Asia.
• Wanbury refinanced high-cost debt of ₹205 crore, bringing interest rates down to sub-10% per annum from 12.5% per annum.
• Promoter pledge encumbrance was reduced with the release of 85.20 lakh pledged shares on July 7, 2026.

Key Takeaways

• EDQM approval for Rivaroxaban API (anticoagulant) paves the way for direct entry into regulated European markets accepting CEPs.
• USFDA DMF clearances for Paroxetine HCl and Metformin HCl API support client ANDA filings and enhance regulatory compliance.
• A marginal top-line growth of 1.47% YoY highlights resilient demand despite severe margin compression from elevated input and logistics costs.
• Balance sheet deleveraging continues with ₹205 crore debt refinanced and the release of substantial promoter-pledged shares.

SAHI Perspective

While Wanbury's near-term profitability took a sharp hit due to inflated solvent costs and West Asian export bottlenecks, the company is systematically upgrading its structural fundamentals. The new EDQM approval and USFDA DMF clearances expand its high-value global generic export market potential. Supported by a significantly lower interest burden from its ₹205 crore debt refinancing, Wanbury is preparing its balance sheet and regulatory pipelines for when commodity cost pressures subside.

Market Implications

The dual regulatory approvals are highly supportive of export volume expansion in future quarters. However, the market is likely to weigh these strategic milestones against the near-term margin erosion highlighted in the quarter ended June 30, 2026. The key to sustainable margin recovery relies on successful passthrough of inflated input costs and immediate commercialization of newly approved APIs.

Trading Signals

Market Bias: Neutral

Positive regulatory approvals from EDQM and USFDA, combined with a debt refinancing of ₹205 crore, are structurally bullish. However, this is heavily offset in the short term by a sharp ≈75.98% YoY net profit decline to ₹3.24 crore due to cost pressures.

Overweight: Pharmaceutical APIs, Anticoagulants, Diabetes Care APIs

Underweight: High-Input Cost Pharma Manufacturers

Trigger Factors:

• Passing through higher raw material costs to customers to restore margins.
• Successful resolution of the USFDA Form 483 observations at the Tanuku facility.
• Commercial scaling and delivery of Rivaroxaban API into European supply chains.

Time Horizon: Medium-term (3-12 months)

Industry Context

The active pharmaceutical ingredient (API) manufacturing landscape is contending with dual headwinds of elevated solvent prices and West Asia transit delays. Despite these macro pressures, major players are focusing on expanding specialty portfolios. Wanbury, which maintains a leading position globally in Metformin manufacturing, is looking to de-risk its product mix by pivoting toward high-margin niches like Rivaroxaban and Paroxetine.

Key Risks to Watch

• Persistent volatility in input cost dynamics for solvents and key chemical intermediates.
• Pending regulatory resolution of the six Form 483 observations issued at the Tanuku plant in July 2026.
• Geopolitical friction points delaying API export dispatches.

Recent Developments

During the quarter ended June 30, 2026, the company's Patalganga facility completed a Korean MFDS inspection with zero observations, while subsequent USFDA reviews cleared its Metformin HCl API on July 30, 2026. However, the Tanuku facility received a USFDA Form 483 with six observations on July 22, 2026.

Closing Insight

Wanbury's dual EDQM and USFDA milestones showcase its commitment to strengthening regulatory pathways. Once short-term supply chain challenges and input costs normalize, the combination of expanded high-margin export capabilities and aggressive debt restructuring should significantly support cash flow and valuation metrics.

High Performance Trading with SAHI.